The Acronym Behind Our Wildest AI Dreams and Nightmares
By Émile P. Torres,
Truthdig
| 06. 15. 2023
TESCREAL—pronounced “tess-cree-all.” It’s a strange word that you may have seen pop up over the past few months. The renowned computer scientist Dr. Timnit Gebru frequently mentions the “TESCREAL” ideologies on social media, and for a while the Twitter profile of billionaire venture capitalist Marc Andreessen read: “cyberpunk activist; embracer of variance; TESCREAList.” The Financial Times, Business Insider and VentureBeat have all used or investigated the word. And The Washington Spectator published an article by Dave Troy titled, “Understanding TESCREAL—The Weird Ideologies Behind Silicon Valley’s Rightward Turn.”
My guess is that the acronym will gain more attention as the topic of artificial intelligence becomes more widely discussed, along with questions about the strange beliefs of its most powerful Silicon Valley proponents and critics. But what the heck does “TESCREAL” mean and why does it matter?
I have thought a lot about these questions, as I coined the term in an as-yet unpublished academic paper, co-written with Gebru, tracing the influence of a small constellation of interrelated and overlapping ideologies within the contemporary field of AI. Those ideologies, we believe, are...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...